Danish vaccine manufacturer Bavarian Nordic reports revenue for the third quarter of 1.36 billion Danish kronor. This was clearly lower than the average forecast of 1.68 billion by stock analysts.
The underlying profit (ebitda) landed at 250 million Danish kronor, half of what stock professionals had predicted.
The company manufactures, among other things, vaccines against the infectious disease mpox, which broke out earlier this year.
Ahead of 2025, the company has secured orders for mpox vaccines worth 2.4 billion Danish kronor.
